CN116783198A - Spirocyclic JAK inhibitor, pharmaceutical composition containing same and application of spiro JAK inhibitor - Google Patents
Spirocyclic JAK inhibitor, pharmaceutical composition containing same and application of spiro JAK inhibitor Download PDFInfo
- Publication number
- CN116783198A CN116783198A CN202180080571.9A CN202180080571A CN116783198A CN 116783198 A CN116783198 A CN 116783198A CN 202180080571 A CN202180080571 A CN 202180080571A CN 116783198 A CN116783198 A CN 116783198A
- Authority
- CN
- China
- Prior art keywords
- group
- compound
- pharmaceutically acceptable
- substitution
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- 229940122245 Janus kinase inhibitor Drugs 0.000 title abstract description 17
- 125000003003 spiro group Chemical group 0.000 title abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 120
- 150000003839 salts Chemical class 0.000 claims abstract description 46
- 102000042838 JAK family Human genes 0.000 claims abstract description 38
- 108091082332 JAK family Proteins 0.000 claims abstract description 38
- 239000012453 solvate Substances 0.000 claims abstract description 30
- 239000000651 prodrug Substances 0.000 claims abstract description 27
- 229940002612 prodrug Drugs 0.000 claims abstract description 27
- 230000003287 optical effect Effects 0.000 claims abstract description 26
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims abstract description 23
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 9
- -1 nitro, hydroxy Chemical group 0.000 claims description 74
- 238000006467 substitution reaction Methods 0.000 claims description 44
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 33
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 20
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 20
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 229940124530 sulfonamide Drugs 0.000 claims description 17
- 150000003456 sulfonamides Chemical class 0.000 claims description 17
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 14
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 150000001408 amides Chemical class 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 12
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 11
- 150000003857 carboxamides Chemical class 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 150000003457 sulfones Chemical class 0.000 claims description 11
- 150000003462 sulfoxides Chemical class 0.000 claims description 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 9
- 125000001624 naphthyl group Chemical group 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 229940043355 kinase inhibitor Drugs 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 4
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- VKWJMTLAAJULGF-UHFFFAOYSA-N methoxymethyl formate Chemical compound COCOC=O VKWJMTLAAJULGF-UHFFFAOYSA-N 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 208000024799 Thyroid disease Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 description 31
- 239000000203 mixture Substances 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 125000000623 heterocyclic group Chemical group 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 14
- BGHCVCJVXZWKCC-UHFFFAOYSA-N tetradecane Chemical compound CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 238000004949 mass spectrometry Methods 0.000 description 11
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 8
- 108010024121 Janus Kinases Proteins 0.000 description 8
- 102000015617 Janus Kinases Human genes 0.000 description 8
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 4
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- RREQTJGQZVVKEK-UHFFFAOYSA-N CC(NC1CCC(CC2)(CN2C2=NC=NC3=C2C=CN3)CC1)=O Chemical compound CC(NC1CCC(CC2)(CN2C2=NC=NC3=C2C=CN3)CC1)=O RREQTJGQZVVKEK-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 3
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 3
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 150000002894 organic compounds Chemical group 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 2
- PEDCOKAJSPIIFY-UHFFFAOYSA-N 2-azaspiro[3.3]heptan-6-one Chemical compound C1C(=O)CC11CNC1 PEDCOKAJSPIIFY-UHFFFAOYSA-N 0.000 description 2
- VJFPYVXEDCMULJ-UHFFFAOYSA-N 2-azaspiro[3.3]heptan-6-one 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1CC2(CNC2)C1 VJFPYVXEDCMULJ-UHFFFAOYSA-N 0.000 description 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- KOPJUOVXCDGGLH-UHFFFAOYSA-N O=C1CCC(CC2)(CN2C2=NC=NC3=C2C=CN3)CC1 Chemical compound O=C1CCC(CC2)(CN2C2=NC=NC3=C2C=CN3)CC1 KOPJUOVXCDGGLH-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 125000005265 dialkylamine group Chemical group 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- UIWISFUVNHCOBJ-UHFFFAOYSA-N ethyl 2-(1,4-dioxaspiro[4.5]decan-8-ylidene)acetate Chemical compound C1CC(=CC(=O)OCC)CCC21OCCO2 UIWISFUVNHCOBJ-UHFFFAOYSA-N 0.000 description 2
- QYADHBOFQDORHO-UHFFFAOYSA-N ethyl 2-[8-(nitromethyl)-1,4-dioxaspiro[4.5]decan-8-yl]acetate Chemical compound C1CC(CC(=O)OCC)(C[N+]([O-])=O)CCC21OCCO2 QYADHBOFQDORHO-UHFFFAOYSA-N 0.000 description 2
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 125000001174 sulfone group Chemical group 0.000 description 2
- 125000000542 sulfonic acid group Chemical group 0.000 description 2
- 125000003375 sulfoxide group Chemical group 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- UCJZOKGUEJUNIO-IINYFYTJSA-N (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@@H]1OCC2(CCN(CC2)C2=CN=C(SC3=C(Cl)C(N)=NC=C3)C(N)=N2)[C@@H]1N UCJZOKGUEJUNIO-IINYFYTJSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- HGYTYZKWKUXRKA-MRXNPFEDSA-N 1-[4-[3-amino-5-[(4S)-4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl]pyrazin-2-yl]sulfanyl-3,3-difluoro-2H-indol-1-yl]ethanone Chemical compound NC=1C(=NC=C(N=1)N1CCC2([C@@H](COC2)N)CC1)SC1=C2C(CN(C2=CC=C1)C(C)=O)(F)F HGYTYZKWKUXRKA-MRXNPFEDSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- RNHWYOLIEJIAMV-UHFFFAOYSA-N 1-chlorotetradecane Chemical class CCCCCCCCCCCCCCCl RNHWYOLIEJIAMV-UHFFFAOYSA-N 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- LTFUAYRGVLQXKC-NTUHNPAUSA-N 1-tert-butyl-3-[(E)-(2,4-dihydroxyphenyl)methylideneamino]thiourea Chemical compound CC(C)(C)NC(=S)N\N=C\c1ccc(O)cc1O LTFUAYRGVLQXKC-NTUHNPAUSA-N 0.000 description 1
- QEVGZEDELICMKH-UHFFFAOYSA-L 2-(carboxylatomethoxy)acetate Chemical compound [O-]C(=O)COCC([O-])=O QEVGZEDELICMKH-UHFFFAOYSA-L 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- PDGKHKMBHVFCMG-UHFFFAOYSA-N 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1'-cyclohexane]-6-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 PDGKHKMBHVFCMG-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- AXRKIZCFYZBBPX-UHFFFAOYSA-N 3-bromo-5-nitrobenzoic acid Chemical compound OC(=O)C1=CC(Br)=CC([N+]([O-])=O)=C1 AXRKIZCFYZBBPX-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- JHSXDAWGLCZYSM-UHFFFAOYSA-N 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide Chemical compound CC1=CC(Cl)=CC=C1OCCCC(=O)NO JHSXDAWGLCZYSM-UHFFFAOYSA-N 0.000 description 1
- JAHIPDTWWVYVRV-UHFFFAOYSA-N 4-chloro-2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1[N+]([O-])=O JAHIPDTWWVYVRV-UHFFFAOYSA-N 0.000 description 1
- BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 1
- ADGGYDAFIHSYFI-UHFFFAOYSA-N 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1 ADGGYDAFIHSYFI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000036174 Actinomycetales Infections Diseases 0.000 description 1
- 208000010920 Actinomycetales infectious disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 229940127277 BI-765063 Drugs 0.000 description 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 1
- 229940124291 BTK inhibitor Drugs 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010013453 Disseminated tuberculosis Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 102000004551 Interleukin-10 Receptors Human genes 0.000 description 1
- 108010017550 Interleukin-10 Receptors Proteins 0.000 description 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 102100026244 Interleukin-9 receptor Human genes 0.000 description 1
- 208000037026 Invasive Fungal Infections Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 1
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- RYBPAUATDDTNQS-UHFFFAOYSA-N O=S(C1=CC=CC=C1)(NC1CCC(CC2)(CN2C2=NC=NC3=C2C=CN3)CC1)=O Chemical compound O=S(C1=CC=CC=C1)(NC1CCC(CC2)(CN2C2=NC=NC3=C2C=CN3)CC1)=O RYBPAUATDDTNQS-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 229940126002 RMC-4630 Drugs 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 108010072819 STAT Transcription Factors Proteins 0.000 description 1
- 102000007078 STAT Transcription Factors Human genes 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229940125811 TNO155 Drugs 0.000 description 1
- 229940126302 TTI-621 Drugs 0.000 description 1
- 229940126301 TTI-622 Drugs 0.000 description 1
- 108010010057 TYK2 Kinase Proteins 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- DVEXZJFMOKTQEZ-JYFOCSDGSA-N U0126 Chemical compound C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N DVEXZJFMOKTQEZ-JYFOCSDGSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HISJAYUQVHMWTA-BLLLJJGKSA-N [6-(2-amino-3-chloropyridin-4-yl)sulfanyl-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl]methanol Chemical compound NC1=NC=CC(=C1Cl)SC1=C(N=C(C(=N1)CO)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C HISJAYUQVHMWTA-BLLLJJGKSA-N 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000024340 acute graft versus host disease Diseases 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 229940070173 bimiralisib Drugs 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical class BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229950003628 buparlisib Drugs 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- WRXDGGCKOUEOPW-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)NS(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 WRXDGGCKOUEOPW-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- SZMJVTADHFNAIS-BJMVGYQFSA-N chidamide Chemical compound NC1=CC(F)=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 SZMJVTADHFNAIS-BJMVGYQFSA-N 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000005366 cycloalkylthio group Chemical group 0.000 description 1
- DCZFGQYXRKMVFG-UHFFFAOYSA-N cyclohexane-1,4-dione Chemical compound O=C1CCC(=O)CC1 DCZFGQYXRKMVFG-UHFFFAOYSA-N 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 229950006418 dactolisib Drugs 0.000 description 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229950004949 duvelisib Drugs 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
- 229950005837 entinostat Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940121280 fimepinostat Drugs 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229950010415 givinostat Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 description 1
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 1
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 1
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 description 1
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 description 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 1
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 description 1
- 108040006862 interleukin-9 receptor activity proteins Proteins 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- YPJRHEKCFKOVRT-UHFFFAOYSA-N lerociclib Chemical compound C1CN(C(C)C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 YPJRHEKCFKOVRT-UHFFFAOYSA-N 0.000 description 1
- 229940121577 lerociclib Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229950009655 milciclib Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- RXZMYLDMFYNEIM-UHFFFAOYSA-N n,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5h-pyrazolo[4,3-h]quinazoline-3-carboxamide Chemical compound CNC(=O)C1=NN(C)C(C2=N3)=C1C(C)(C)CC2=CN=C3NC(C=C1)=CC=C1N1CCN(C)CC1 RXZMYLDMFYNEIM-UHFFFAOYSA-N 0.000 description 1
- OAMVGUFHZPRXOM-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfinylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 OAMVGUFHZPRXOM-UHFFFAOYSA-N 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- JOWXJLIFIIOYMS-UHFFFAOYSA-N n-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound C1=NC(OC)=CC=C1C1=NC(N2CCOCC2)=C(SC(CN(C)C=2N=CC(=CN=2)C(=O)NO)=C2)C2=N1 JOWXJLIFIIOYMS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 description 1
- 229950008089 omipalisib Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 229910052611 pyroxene Inorganic materials 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940121497 sintilimab Drugs 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950001269 taselisib Drugs 0.000 description 1
- HQHRAGXKFOTSQE-UHFFFAOYSA-N tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC21CC(=O)C2 HQHRAGXKFOTSQE-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- PHCBRBWANGJMHS-UHFFFAOYSA-J tetrasodium;disulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O PHCBRBWANGJMHS-UHFFFAOYSA-J 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- 229950007127 trilaciclib Drugs 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 229950001415 tucidinostat Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229950000815 veltuzumab Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
The invention relates to a spiro JAK inhibitor, a pharmaceutical composition containing the spiro JAK inhibitor and application of the spiro JAK inhibitor. Specifically, the invention relates to a compound shown in a formula I or a stereoisomer or an optical isomer, pharmaceutically acceptable salt, prodrug or solvate thereof, a pharmaceutical composition of the compound and a medical application of the compound serving as a JAK inhibitor in preparing medicaments for preventing and/or treating JAK, especially JAK1 related diseases.
Description
The invention belongs to the field of pharmaceutical chemistry, and particularly relates to a spiro JAK inhibitor, a pharmaceutical composition containing the spiro JAK inhibitor and application of the spiro JAK inhibitor.
Protein Kinases (PKs) are a group of enzymes that regulate a variety of important biological processes, including in particular cellular kinases that catalyze the phosphorylation of proteins, lipids, sugars, nucleosides, and other cellular metabolites and play a key role in all aspects of eukaryotic cell physiology, which constitute one of the largest families of enzymes in humans. Abnormal kinase activity has been shown to be involved in many human diseases including cancer, autoimmune diseases and inflammatory diseases.
Janus kinases (JAKs) are cytoplasmic tyrosine kinases that transduce cytokine signals from membrane receptors to STAT transcription factors, which play an important role in cytokine signaling. The JAK family includes four members JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK 2). JAKs are typically associated in pairs with cytokine receptors as homodimers or heterodimers. Cytokines bind to their receptors, causing dimerization of the receptor molecules, and JAKs coupled to the receptors come close to each other and are activated by the phosphorylation of interacting tyrosine residues. The JAK family transmits cytokine-mediated signals into cells through the JAK-STAT (signal transduction and transcription activator) pathway.
Signal transduction and transcription activators (Signal Transducer and Activator of Transcription, STAT) are a group of cytoplasmic proteins that bind to target gene regulatory region DNA. As a downstream substrate of JAKs, STATs can be activated by tyrosine phosphorylation under stimulation of an external signal, and then transferred into the transcription of nuclear regulatory genes. When cytokines bind to their receptors, JAK family members autophosphorylate and/or transphosphorylate each other, followed by stat phosphorylation and then migrate into the nucleus to regulate transcription.
Many abnormal immune responses, such as autoimmune diseases like allergy, asthma, (allograft) transplant rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis, hematological malignancies like myeloproliferative disorders, leukemia and lymphoma, are all associated with JAK/STAT signaling pathways.
Studies have shown that blocking signal transduction at the JAK kinase level offers promise for the development of therapeutic approaches to inflammatory diseases, autoimmune diseases, myeloproliferative diseases, and cancer. Inhibition of JAK kinases also contributes to the treatment of skin immune diseases such as psoriasis and skin sensitization. Toficitinib (Fascitinib) with a pyroxene has been marketed for the treatment of rheumatoid arthritis; and Incyte's ruxotinib for treating myelofibrosis and acute graft versus host disease.
However, some JAK enzyme inhibitors currently available also have some significant toxic side effects, for example, some JAK inhibitors are prone to cause the following side effects: infections including pneumonia, viral infections (e.g. herpes zoster infection), bacterial infections, actinomycete infections (mycobacterial infections), fungal infections, reduced immunity (e.g. NK cytopenia) and anaemia. In the united states, black boxes are alerted even by a portion of serious side effects including, for example, acute tuberculosis, invasive fungal infections, bacterial infections, and a portion of lymphomas or other tumors. Studies have shown that currently available JAK inhibitors tend to have inhibitory activity against both JAK1 and JAK3, and that most of these side effects are associated with inhibited JAK3 activity.
However, studies have shown that JAKs family kinases are responsible for regulating numerous signaling pathways. Since JAK1 and JAK3 are part of the common gamma-chain cytokine receptor complex, this has resulted in great difficulty in developing inhibitors with high selectivity for JAK 1.
JAK1 plays a key role in the regulation of biological responses, and JAK1 is widely expressed and associated with several major cytokine receptor families. It is involved in signaling through members of the IL-2 receptor gamma subunit family (IL-2, IL-4, IL-7R, IL-9R, IL-15R and IL-21R), the IL-4 receptor family (IL-4R, IL-13R), the gp130 receptor family and the class II cytokine receptors (including the IL-10 receptor family and both the type I and type II IFN receptor families).
In view of the foregoing, there is a strong need in the art to develop inhibitors of Janus kinases or related kinases, particularly inhibitors with high selectivity for JAK 1.
Disclosure of Invention
The present invention provides inhibitors of JAK or related kinases, particularly inhibitors having high selectivity for JAK 1.
In a first aspect of the present invention there is provided a compound of formula I or a stereoisomer or optical isomer, a pharmaceutically acceptable salt, prodrug or solvate thereof,
In the method, in the process of the invention,
R 1 、R 2 and R is 3 Each independently selected from the group consisting of substituted or unsubstituted: H. d, halogen, amino, nitro, hydroxy, cyano, carboxyl, sulfone, sulfoxide, amide, sulfonamide, ester, formylAmino, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, 3-to 10-membered heterocycloalkyl, C3-C10 cycloalkyl, 5-to 12-membered heteroaryl, C6-C12 aryl; wherein said substitution means by one or more R a Substitution;
or R is 1 And R is 2 Together with the atoms to which they are attached, constitute a substituted or unsubstituted group of radicals: 5-6 membered aryl or heteroaryl, 3-10 membered heterocycloalkyl, C3-C10 cycloalkyl; wherein said substitution means by one or more R a Substitution;
b is independently selected from the group consisting of: bond, - (CH) 2 ) r -、C(=O)、N-R b 、C(=O)O-、 -(CH 2 ) p -R c 、O、S、SO、SO 2 ;R c Selected from: c (=O) O-, C (=O) O-Wherein R is b Independently selected from the group consisting of: H. C1-C6 alkyl;
wherein- (CH) 2 ) r -and- (CH) 2 ) p The H atom in-can optionally be replaced by one or more R a Substitution;
c is selected from the group consisting of substituted or unsubstituted: H. C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, 3-to 10-membered heterocycloalkyl, C3-C10 cycloalkyl, 5-to 12-membered heteroaryl, C6-C12 aryl; wherein said substitution means by one or more R a Substitution;
r and p are each independently 1, 2, 3, 4;
m, n, k and l are each independently 0, 1, 2, 3, and m+n is not less than 1, k+l is not less than 1;
h in the moiety may optionally be substituted with one or more R a Substitution;
wherein each R a Independently selected from the group consisting of substituted or unsubstituted: halogen, amino, nitro, hydroxyl, mercapto, cyano, carboxyl, sulfone, sulfoxide, amide, sulfonamide, ester, formyl, carboxamide, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, 3-C10 membered heterocycloalkyl, C3-C10 cycloalkyl, 5-12 membered heteroaryl and C6-C12 aryl; wherein R is a By substitution is meant substitution with one or more groups selected from the group consisting of: halogen, amino, nitro, hydroxyl, mercapto, cyano, carboxyl, sulfone, sulfoxide, amide, sulfonamide, ester, formyl, carboxamide, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, 3-to 10-membered heterocycloalkyl, C3-to 10-cycloalkyl, 5-to 12-membered heteroaryl and C6-C12-aryl.
In another preferred embodiment, the compound of formula I or a stereoisomer or optical isomer, pharmaceutically acceptable salt, prodrug or solvate thereof,
In the method, in the process of the invention,
R 1 、R 2 and R is 3 Each independently selected from the group consisting of substituted or unsubstituted: H. d, halogen, amino, nitro, hydroxy, cyano, carboxyl, sulfone, sulfoxide, amide, sulfonamide, ester, formyl, carboxamide, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, 3-C10 membered heterocycloalkyl, C3-C10 cycloalkyl, 5-12 membered heteroaryl, C6-C12 aryl; wherein said substitution means by one or more R a Substitution;
or R is 1 And R is 2 To which are attached atoms oneTo constitute the substituted or unsubstituted group: 5-6 membered aryl or heteroaryl, 3-10 membered heterocyclyl, C3-C10 cycloalkyl; wherein said substitution means by one or more R a Substitution;
b is independently selected from the group consisting of: bond, - (CH) 2 ) r -、C(=O)、N-R b 、C(=O)O-、 -(CH 2 ) p -R c 、O、S、SO、SO 2 ;R c Selected from: c (=O) O-, C (=O) O-Wherein R is b Independently selected from the group consisting of: H. C1-C6 alkyl;
wherein- (CH) 2 ) r -and- (CH) 2 ) p The H atom in-can optionally be replaced by one or more R a Substitution;
c is selected from the group consisting of substituted or unsubstituted: C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, 3-to 10-membered heterocycloalkyl, C3-C10 cycloalkyl, 5-to 12-membered heteroaryl, C6-C12 aryl; wherein said substitution means by one or more R a Substitution;
r and p are each independently 1, 2, 3, 4;
m, n, k and l are each independently 0, 1, 2, 3, and m+n is not less than 1, k+l is not less than 1;
h in the moiety may optionally be substituted with one or more R a Substitution;
wherein each R a Independently selected from the group consisting of substituted or unsubstituted: halogen, amino, nitroHydroxyl, mercapto, cyano, carboxyl, sulfone, sulfoxide, amide, sulfonamide, ester, formyl, carboxamide, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, 3-10 membered heterocycloalkyl, C3-C10 cycloalkyl, 5-12 membered heteroaryl, and C6-C12 aryl; wherein R is a By substitution is meant substitution with one or more groups selected from the group consisting of: halogen, amino, nitro, hydroxyl, mercapto, cyano, carboxyl, sulfone, sulfoxide, amide, sulfonamide, ester, formyl, carboxamide, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, 3-to 10-membered heterocycloalkyl, C3-to 10-cycloalkyl, 5-to 12-membered heteroaryl and C6-C12-aryl.
In another preferred embodiment, each R a Independently selected from the group consisting of: halogen, amino, nitro, hydroxy, mercapto, cyano, carboxyl, sulfone, sulfoxide, amide, sulfonamide, ester, formyl, carboxamide, C1-C6 alkyl, halogenated C1-C6 alkyl, (CH) 2 ) t G. C1-C6 alkoxy, haloC 1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, 3-to 10-membered heterocycloalkyl, C3-C10 cycloalkyl, 5-to 12-membered heteroaryl and C6-C12 aryl, wherein t is 1, 2 or 3; g is selected from: 3-10 membered heterocycloalkyl, C3-C10 cycloalkyl, 5-12 membered heteroaryl and C6-C12 aryl.
In another preferred embodiment, the compound or a stereoisomer or optical isomer, pharmaceutically acceptable salt, prodrug or solvate thereof,the moiety is selected from:
wherein q is 0, 1, 2, 3, 4 or 5;
R a is defined as above.
In another preferred embodiment, the compound or stereoisomer or optical isomer, pharmaceutically acceptable salt, prodrug or solvate thereof has a structure shown in formula II:
wherein q is 0, 1, 2, 3, 4 or 5;
R 1 、R 2 、R 3 、R a the definitions of B and C are as described above.
In another preferred embodiment, the compound or stereoisomer or optical isomer, pharmaceutically acceptable salt, prodrug or solvate thereof, B is selected from the group consisting of: c (=O) O-, C (=O) O-Wherein R is b Is defined above.
In another preferred embodiment, the compound or stereoisomer, or optical isomer, pharmaceutically acceptable salt, prodrug or solvate thereof, C is selected from the group consisting of substituted or unsubstituted: 3-8 membered heterocycloalkyl, C3-C8 cycloalkyl, 5-10 membered heteroaryl, C6-C10 aryl; wherein said substitution means by one or more R a Substitution;
R a is defined as above.
In another preferred embodiment, C is selected from the group consisting of substituted or unsubstituted: cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyrrolyl, tetrahydropyranyl, piperazinyl, piperidinyl, morpholinyl, phenyl, pyridinyl, pyrimidinyl, imidazolyl, pyrazolyl, furanyl, thiazolyl, pyrrolyl, indolyl, naphthyl, wherein the substitution means by one or more R a Substitution; r is R a Is defined as above.
In a further preferred embodiment of the present invention,selected from:
wherein q is 0, 1, 2, 3, 4 or 5;
R a is defined as above.
In another preferred embodiment, B is selected from: -NH-,-NH-C (=o) -, optionally each hydrogen in the above groups being substituted by a C1-C6 alkyl group.
In another preferred embodiment, C is selected from: H. methoxy, phenyl, methyl, ethyl, thiazolyl, pyridyl, cyclopropyl, pyrazinyl, cyclohexyl, benzothienyl, benzofuranyl, pyrimidinyl, naphthyl, cyclobutyl, cyclopentyl, cycloheptyl; wherein, optionally, C is substituted with a substituent selected from the group consisting of: fluorine, chlorine, bromine, nitro, cyano, hydroxy, ethynyl, methyl, methoxy, methyl formate, trifluoromethyl, phenyl, sulfamoyl (or sulfonamide).
In another preferred embodiment, C is selected from: H. methoxy, phenyl, methyl, ethyl,Cyclopropyl group,Cyclohexyl group,Naphthyl, cyclobutyl, cyclopentyl, cycloheptyl; wherein, optionally, C is substituted with a substituent selected from the group consisting of: fluorine, chlorine, bromine, nitro, cyano, hydroxy, ethynyl, methyl, methoxy, methyl formate, trifluoromethyl, phenyl, sulfamoyl (or sulfonamide).
In another preferred embodiment, C is selected from: H. methyl, methoxy, Phenyl group,
In another preferred embodiment, R 1 Is hydrogen.
In another preferred embodiment, R 2 Is hydrogen.
In another preferred embodiment, R 3 Is hydrogen.
In a further preferred embodiment of the present invention,selected from the group consisting of
In another preferred embodiment, the compound has the structure shown in formula II:
wherein q is 0, 1, 2, 3, 4 or 5;
R 1 、R 2 、R 3 、R a the definitions of B and C are as described above.
In another preferred embodiment, each C1-C6 alkyl is independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl.
In another preferred embodiment, each C1-C6 alkoxy group is independently selected from methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy.
In another preferred embodiment, each C2-C6 alkenyl is independently selected from ethenyl, propenyl, allyl.
In another preferred embodiment, each C2-C6 alkynyl is independently selected from ethynyl, propynyl.
In another preferred embodiment, each 3-10 membered heterocycloalkyl is independently selected from tetrahydrofuranyl, tetrahydropyrrolyl, tetrahydrothiophene, tetrahydropyranyl, piperazinyl, piperidinyl, morpholinyl.
In another preferred embodiment, each C3-C10 cycloalkyl is independently selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl.
In another preferred embodiment, each 5-12 membered heteroaryl is independently selected from the group consisting of pyrrolyl, furanyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, thiazolyl, indolyl, benzothienyl, benzofuranyl.
In another preferred embodiment, each C6-C12 aryl is independently selected from phenyl, naphthyl.
In another preferred embodiment, in formula I, R 1 、R 2 、R 3 、R a And B and C are specific groups corresponding to specific compounds in the examples.
In another preferred embodiment, the compound or a stereoisomer or optical isomer, pharmaceutically acceptable salt, prodrug or solvate thereof is selected from the group consisting of:
in another preferred embodiment, the compound of formula I is selected from the compounds shown in the examples.
In a second aspect of the invention there is provided a pharmaceutical composition comprising a compound of the first aspect or a stereoisomer or optical isomer thereof, a pharmaceutically acceptable salt, prodrug or solvate thereof; and a pharmaceutically acceptable carrier.
In another preferred embodiment, the pharmaceutical composition further comprises a drug selected from the group consisting of:
PD-1 inhibitors (such as nivolumab, pembrolizumab, pidilizumab, cemiplimab, JS-001, SHR-120, BGB-A317, IBI-308, GLS-010, GB-226, STW204, HX008, HLX10, BAT1306, AK105, LZM 009, or biological analogues of the above, etc.), PD-L1 inhibitors (such as Devacizumab, emamizumab, avstumab (avelumab), CS1001, KN035, HLX20, SHR-1316, BGB-A333, JS003, CS1003, KL-A167, F520, GR1405, MSB2311, or biological analogues of the above, etc.), CD20 antibodies (such as rituximab, obabine You Tuozhu monoclonal antibody, ofatuzumab, veltuzumab, toximomab, 131I-toximomab, temozolomab, 90Y-temozolomab, 90 In-temozolomab, temozolomab (ibritumomab tiuxetan), etc.), CD47 antibodies (e.g., hu5F9-G4, CC-90002, TTI-621, TTI-622, OSE-172, SRF-231, ALX-148, NI-1701, SHR-1603, IBI188, IMM 01), ALK inhibitors (e.g., ceritinib, ai Leti, buntinib, latinib, okatinib), PI3K inhibitors (e.g., aitiritinib, duvelisib, dactolisib, taselisib, bimiralisib, omipalisib, buparlisib, etc.), BTK inhibitors (e.g., ibrutinib, tirabutenib, acartinib, etc.), EGFR inhibitors (e.g., africtinib, gefitinib, erlotinib, lapatinib, dactinib, ecritinib, katinib, qtinib, uvalatinib, etc.), utinib, natinib, uvalatinib, uvalnemab, utinib, UK inhibitors (e.g., nacritinib, qeritinib, qerib, etc.), altinib, qeritinib, etc. Pazopanib, regorafenib, selatinib, nisrotinib, cabozantinib, sunitinib, dorafinib, and the like), HDAC inhibitors (e.g., givinostat, tucidinostat, vorinostat, fimepinostat, droxinostat, entinostat, darsitpristine, quesinostat, tacroline, and the like), CDK inhibitors (e.g., pamazetinib, rebamiptinib, abemaciclib, milciclib, trilaciclib, lerociclib, and the like), MEK inhibitors (e.g., semantenib (AZD 6244), trametinib (GSK 1120212), PD0325901, U0126, pimasertib (AS-703026), PD184352 (CI-1040, and the like), mTOR inhibitors (e.g., vistuertib, and the like), SHP2 inhibitors (e.g., RMC-4630, JAB-3068, TNO155, and the like), or combinations thereof.
In a third aspect of the present invention, there is provided a method of preparing a pharmaceutical composition comprising the steps of: mixing a pharmaceutically acceptable carrier with a compound of the first aspect of the invention or a stereoisomer or optical isomer thereof, a pharmaceutically acceptable salt, prodrug or solvate thereof, thereby forming a pharmaceutical composition.
In another preferred embodiment, the compounds of the present invention may be formulated into powders, tablets, granules, capsules, solutions, emulsions, suspensions, and the like.
In another preferred embodiment, the pharmaceutical composition is used for treating or preventing a disease associated with the activity or expression of JAK kinase.
In another preferred embodiment, the pharmaceutical composition is used as a JAK kinase inhibitor, preferably as a JAK1 kinase inhibitor.
In a fourth aspect, the present invention provides a compound according to the first aspect or a stereoisomer or an optical isomer, a pharmaceutically acceptable salt, a prodrug or a solvate thereof for use in the preparation of a medicament or a pharmaceutical composition for the treatment or prevention of a disease associated with the activity or expression of JAK kinase.
In another preferred embodiment, the disease is selected from the group consisting of: cancer, myeloproliferative diseases, inflammation, immune diseases, organ transplantation, viral diseases, cardiovascular diseases or metabolic diseases, autoimmune diseases of humans or animals, rheumatoid arthritis, skin disorders, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, myasthenia gravis, psoriasis.
Wherein the cancer is selected from the group consisting of: prostate cancer, kidney cancer, liver cancer, breast cancer, lung cancer, thyroid cancer, kaposi's sarcoma, giant lymphoproliferative disorders, pancreatic cancer, leukemia, lymphoma, multiple myeloma.
In another preferred embodiment, the disease associated with the activity or expression level of JAK kinase is a JAK 1-related disorder.
Wherein the JAK 1-associated disorder is preferably selected from the group consisting of: type I diabetes, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, crohn's disease and alopecia areata.
In another preferred embodiment, there is provided the use of a compound of the first aspect, or a stereoisomer or optical isomer, pharmaceutically acceptable salt, prodrug or solvate thereof, for the preparation of a medicament or pharmaceutical composition for inhibiting JAK kinase activity; wherein the JAK kinase is preferably a JAK1 kinase.
It is understood that within the scope of the present invention, the above-described technical features of the present invention and technical features specifically described below (e.g., in the examples) may be combined with each other to constitute new or preferred technical solutions. And are limited to a space, and are not described in detail herein.
The present inventors have found, for the first time, through extensive and intensive studies, a novel JAK inhibitor which is novel in structure and has excellent bioactivity and extremely excellent selectivity against JAK 1. Specifically, the selectivity of the compounds of the present invention represented by the ratio of JAK2/JAK1 or the selectivity represented by the ratio of JAK3/JAK1 or the ratio of TYK2/JAK1 is increased about 10-fold on average (most compounds are increased about 20-100-fold). Thus, the side effects of the compounds of the invention associated with JAK3 inhibition are extremely reduced, while safety will be significantly improved. The present invention has been completed on the basis of this finding.
Terminology
In the present invention, unless otherwise indicated, terms used have the ordinary meanings known to those skilled in the art.
When substituents are described by conventional formulas written from left to right, the substituents also include chemically equivalent substituents obtained when writing formulas from right to left. That is, when the linking group-L1-as exemplified in the present invention does not indicate the linking direction, the linking direction may be in the same direction as the reading order from left to right, or may be in the opposite direction to the above. As will be illustrated by way of example, The linking group-L1-is-C-D-, if-C-D-is formed by linking the ring A and the ring B in the same direction as the reading sequence from left to rightif-C-D-is formed by connecting rings A and B in a direction opposite to the above-mentioned direction
The term "optional" or "optionally" means that the subsequently described event or circumstance may, but need not, occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
As used herein, when used in reference to a specifically recited value, the term "about" means that the value can vary no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes 99 and 101 and all values therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
As used herein, the term "comprising" or "including" can be open, semi-closed, and closed. In other words, the term also includes "consisting essentially of …," or "consisting of ….
As used herein, the term "alkyl" includes straight or branched chain alkyl groups. For example C 1 -C 6 Alkyl means a straight or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, etc.
As used herein, the term "alkenyl" includes straight or branched alkenyl groups. For example C 2 -C 6 Alkenyl refers to straight or branched alkenyl groups having 2 to 6 carbon atoms such as vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, or the like.
Such as the bookAs used herein, the term "alkynyl" includes straight or branched chain alkynyl groups. For example C 2 -C 6 Alkynyl refers to straight or branched chain alkynyl groups having 2 to 6 carbon atoms, such as ethynyl, propynyl, butynyl, or the like.
As used herein, the term "cycloalkyl" refers to a cyclic alkyl group (saturated or containing double bonds) containing a specified number of C atoms, e.g. "C3-C10 cycloalkyl" refers to cycloalkyl groups having 3-10 (preferably 3, 4, 5, 6, 7 or 8) carbon atoms. It may be a single ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or the like. But also in the form of a bicyclic ring, for example a bridged or spiro ring. In the present invention, cycloalkyl is intended to include substituted cycloalkyl.
As used herein, the term "C1-C6 alkoxy" refers to a straight or branched chain alkoxy group having 1 to 6 carbon atoms; having the formula C1-C6 alkyl-O-or-C1-C5 alkyl-O-C1-C5 alkyl (e.g., -CH) 2 -O-CH 2 CH 3 、-CH 2 -O-(CH 2 ) 2 CH 3 、-CH 2 CH 2 -O-CH 2 CH 3 ) Structure such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy and the like.
As used herein, "heterocyclyl" refers to a saturated or partially saturated cyclic group having heteroatoms selected from N, S and O, and "3-10 membered heterocyclyl" refers to a saturated or partially saturated cyclic group having 3-10 atoms and wherein 1-3 atoms are heteroatoms selected from the following groups N, S and O. In the present invention, the heterocyclic group and the heterocycloalkyl group have the same meaning and are used interchangeably. It may be a single ring or may be in the form of a double ring, for example in the form of a bridged or spiro ring. The 3-to 10-membered heterocyclic (alk) yl group is preferably a 3-to 8-membered heterocyclic (alk) yl group, more preferably a 6-to 8-membered heterocyclic (alk) yl group. Specific examples may be oxetane, azetidine, tetrahydro-2H-pyranyl, piperidinyl, piperazinyl, tetrahydrofuranyl, morpholinyl, pyrrolidinyl and the like.
As used herein, "aryl" refers to an aromatic cyclic group containing no heteroatoms in the ring, and "C6-C12 aryl" refers to an aromatic cyclic group containing 6 to 12 carbon atoms containing no heteroatoms in the ring, which may be fused to a heteroaryl, heterocyclic or cycloalkyl ring, wherein the ring attached to the parent structure is an aryl ring. Such as phenyl (i.e., six-membered aromatic ring), naphthyl, and the like, wherein six-membered aryl is also intended to include six-membered aryl-5-6 membered cycloalkyl and six-membered aryl-5-6 membered heterocycloalkyl. The C6-C12 aryl group is preferably a C6-C10 aryl group. Aryl groups may be optionally substituted or unsubstituted.
As used herein, "heteroaryl" refers to a cyclic aromatic group having 1-3 atoms that are heteroatoms selected from the following groups N, S and O, and "5-12 membered heteroaryl" refers to a cyclic aromatic group having 5-12 atoms and wherein 1-3 atoms are heteroatoms selected from the following groups N, S and O. It may be a single ring or may be in the form of a fused ring. Specific examples may be pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1, 2, 3) -triazolyl, and (1, 2, 4) -triazolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, and the like. The heteroaryl ring may be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring attached to the parent structure is a heteroaryl ring. Heteroaryl groups may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more groups independently selected from alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, alkylthio, alkylamino, halogen, amino, nitro, hydroxy, mercapto, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylthio, oxo, amido, sulfonamide, formyl, carboxamide, carboxyl, carboxylate and the like.
As used herein, "halogen" or "halogen atom" refers to F, cl, br, and I. More preferably, the halogen or halogen atom is selected from F, cl and Br.
In the present invention, the term "amide" refers to a group with the structure-CONRR ', wherein R and R' may independently represent hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl, as defined above. R and R' may be the same or in the dialkylamine fragmentDifferent. Examples of amide groups include, but are not limited to: -CONH 2 、-CONHCH 3 、-CONHCH 2 CH 3 、-CON(CH 3 ) 2 -CONH cyclopropyl, -CONH cyclobutyl, -CONH cyclopentyl, -CONH cyclohexyl, -CONCH 3 Cyclopropyl, -CONCH 3 Cyclobutyl, -CONCH 3 Cyclopentyl, -CONCH 3 And a cyclohexyl group.
In the present invention, the term "sulfonamide" refers to a compound having the structure-SO 2 The group NRR 'wherein R and R' may independently represent hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl, as defined above. R and R' may be the same or different in the dialkylamine fragment. Examples of sulfonamide groups include, but are not limited to: -SO 2 NH 2 、-SO 2 NHCH 3 、-SO 2 NHCH 2 CH 3 、-SO 2 N(CH 3 ) 2 、-SO 2 NH cyclopropyl, -SO 2 NH cyclobutyl, -SO 2 NH cyclopentyl, -SO 2 NH cyclohexyl, -SO 2 NCH 3 Cyclopropyl, -SO 2 NCH 3 Cyclobutyl, -SO 2 NCH 3 Cyclopentyl, -SO 2 NCH 3 And a cyclohexyl group.
In the present invention, the term "formyl" refers to a group comprising-CHO.
In the present invention, the term "carboxamide group" is meant to includeThe carboxamide group is also intended to comprise a substituted carboxamide group having the formulaWherein R each independently represents hydrogen, alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heteroarylCyclic groups, as defined above. Each R may be the same or different.
In the present invention, "amino" means having a structure of-N-RR ', R and R ' each independently represent hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, as defined above, and R ' may be the same or different. Examples of amino groups include, but are not limited to: -NH 2 、-NHCH 3 、-NHCH 2 CH 3 、-N(CH 3 ) 2 -NH cyclopropyl, -NH cyclobutyl, -NH cyclopentyl, -NH cyclohexyl, -NCH 3 Cyclopropyl, -NCH 3 Cyclobutyl, -NCH 3 Cyclopentyl, -NCH 3 And a cyclohexyl group.
In the present invention, "sulfoxide group" means having-S (O) -R, R independently represents hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, as defined above. Examples of sulfoxide groups include, but are not limited to: -S (O) -CH 3 、-S(O)-CH 2 CH 3 、-S(O)-CH(CH 3 ) 2 。
In the present invention, "sulfone group" means having-S (O) 2 -R, R independently represent hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, as defined above. Examples of sulfone groups include, but are not limited to: s (O) 2 -CH 3 、-S(O) 2 -CH 2 CH 3 、-S(O) 2 -CH(CH 3 ) 2 。
In the present invention, "ester" means having the structure-C (O) -O-R or R-C (O) -O-, wherein, R independently represents hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, as defined above. Examples of ester groups include, but are not limited to: -C (O) -O-CH 3 、-C(O)-O-CH 2 CH 3 、-C(O)-O-CH 2 CH 2 CH 3 、-C(O)-O-CH(CH 3 ) 2 、-O-C(O)-CH 3 、-O-C(O)-CH 2 CH 3 、-O-C(O)-CH 2 CH 2 CH 3 、-O-C(O)-CH(CH 3 ) 2 。
In the present invention, the term "substituted" means that one or more hydrogen atoms on a particular group are replaced with a particular substituent. The specific substituents are those described in the foregoing for each of the examples or are those found in each of the examples. Unless otherwise specified, a substituted group may have a substituent selected from a specific group at any substitutable site of the group, which may be the same or different at each position. Those skilled in the art will appreciate that combinations of substituents contemplated by the present invention are those that are stable or chemically achievable.
Unless otherwise indicated as "substituted or unsubstituted", the radicals according to the invention may be substituted by substituents selected from the group consisting of: deuterium, halogen, cyano, nitro, hydroxy, amino, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, 3-to 10-membered heterocycloalkyl, C3-C10 cycloalkyl, 5-to 12-membered heteroaryl, C6-C12 aryl.
In the present invention, the term "plurality" independently means 2, 3, 4, 5.
Unless otherwise specified, the structural formulae described herein are intended to include all isomeric forms (e.g., enantiomers, diastereomers and geometric isomers (or conformational isomers)): for example R, S configuration containing asymmetric centers, the (Z), (E) isomers of double bonds, etc. Thus, individual stereochemical isomers of the compounds of the invention or mixtures of enantiomers, diastereomers or geometric isomers (or conformational isomers) thereof are all within the scope of the invention.
As used herein, the term "tautomer" means that structural isomers having different energies may exceed the low energy barrier, thereby interconverting. For example, proton tautomers (i.e., proton transfer) include tautomers by proton transfer, such as 1H-indazole and 2H-indazole. Valence tautomers include tautomers that undergo interconversion by recombination of some of the bond-forming electrons.
As used herein, the term "solvate" refers to a compound of the invention that coordinates to a solvent molecule to form a complex in a specific ratio.
Active ingredient
As used herein, "compounds of the invention" refers to compounds of formula I, and also includes stereoisomers or optical isomers, pharmaceutically acceptable salts, prodrugs or solvates of the compounds of formula I.
The compounds of formula I of the present invention have the following structure,
wherein R is 1 、R 2 、R 3 The definitions of B, C, m, n, k and l are as described above.
Preferably, the compound of formula I has the structure described in formula II,
wherein R is 1 、R 2 、R 3 、R a The definitions of q, B and C are as described above.
Preferably, in formulas I-II, B is selected from the group consisting of: c (=O) O-, C (=O) O-Wherein R is b Is defined as above.
Preferably, in formulae I-II, C is selected from the group consisting of substituted or unsubstituted: 3-8 membered heterocycloalkyl, C3-C8 cycloalkyl, 5-10 membered heteroaryl, C6-C10 aryl; preferably, C is selected from substituted or unsubstitutedThe following groups: cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyrrolyl, tetrahydropyranyl, piperazinyl, piperidinyl, morpholinyl, phenyl, pyridinyl, pyrimidinyl, imidazolyl, pyrazolyl, furanyl, thiazolyl, pyrrolyl, indolyl, naphthyl, wherein said substitution is by one or more R a Substitution;
R a is defined as above.
Salts which may be formed with the compounds of the present invention are also within the scope of the present invention. Unless otherwise indicated, the compounds of the present invention are understood to include salts thereof. The term "salt" as used herein refers to salts formed with inorganic or organic acids and bases in the acid or base form. Furthermore, when the compound of the present invention contains a basic moiety, it includes, but is not limited to, pyridine or imidazole, and an acidic moiety, including, but not limited to, carboxylic acids, the possible formation of zwitterions ("inner salts") are included within the term "salts". Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful, for example, in isolation or purification steps during the preparation process. The compounds of the invention may form salts, for example, by reacting compound I with an amount of, for example, an equivalent of, an acid or base, salting out in a medium, or lyophilizing in aqueous solution.
The compounds of the present invention contain basic fragments, including but not limited to amine or pyridine or imidazole rings, which may form salts with organic or inorganic acids. Typical acids that may be salified include acetates (e.g., with acetic acid or trihaloacetic acid, such as trifluoroacetic acid), adipates, alginates, ascorbates, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, diglycolate, dodecyl sulfate, ethane sulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, caproate, hydrochloride, hydrobromide, hydroiodide, hydroxyethanesulfonate (e.g., 2-hydroxyethanesulfonate), lactate, maleate, mesylate, naphthalene sulfonate (e.g., 2-naphthalene sulfonate), nicotinate, nitrate, oxalate, pectate, persulfate, phenylpropionate (e.g., 3-phenylpropionate), phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate (e.g., formed with sulfuric acid), sulfonate, tartrate, thiocyanate, toluene sulfonate such as p-toluenesulfonate, dodecanoate, and the like.
Certain compounds of the present invention may contain acidic moieties, including but not limited to carboxylic acids, that may form salts with various organic or inorganic bases. Typical base-forming salts include ammonium salts, alkali metal salts such as sodium, lithium, potassium salts, alkaline earth metal salts such as calcium, magnesium salts, and salts with organic bases (e.g., organic amines), such as benzathine, dicyclohexylamine, hydrabamine (salts with N, N-bis (dehydroabietyl) ethylenediamine), N-methyl-D-glucamine, N-methyl-D-glucamide, t-butylamine, and salts with amino acids such as arginine, lysine, and the like. Basic nitrogen-containing groups can be combined with halide quaternary ammonium salts, such as small molecule alkyl halides (e.g., methyl, ethyl, propyl and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl and dipentyl sulfates), long chain halides (e.g., decyl, dodecyl, tetradecyl and tetradecyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenyl bromides), and the like.
Prodrugs and solvates of the compounds of the invention are also within the scope of coverage. The term "prodrug" as used herein refers to a compound that undergoes chemical conversion by metabolic or chemical processes to produce a compound, salt, or solvate of the invention when used in the treatment of a related disorder. The compounds of the present invention include solvates, such as hydrates.
The compounds, salts or solvates of the present invention, may exist in tautomeric forms (e.g., amides and imine ethers). All of these tautomers are part of the present invention.
Stereoisomers of all compounds (e.g., those having asymmetric carbon atoms which may be present as a result of various substitutions), including enantiomeric and diastereoisomeric forms thereof, are contemplated as falling within the scope of the present invention. The individual stereoisomers of the compounds of the invention may not be present simultaneously with the other isomers (e.g., having particular activity as one pure or substantially pure optical isomer), or may be mixtures, such as racemates, or mixtures with all or a portion of the other stereoisomers. The chiral center of the present invention has two configurations, S or R, defined by the International Association of theory and application chemistry (IUPAC) 1974. The racemic forms can be resolved by physical methods, such as fractional crystallization, or by separation of crystals by derivatization into diastereomers, or by chiral column chromatography. Individual optical isomers may be obtained from the racemates by suitable methods, including but not limited to conventional methods, such as salt formation with an optically active acid followed by recrystallization.
The compounds of the present invention are prepared, isolated and purified in sequence to give the compounds in an amount of 90% by weight or more, for example 95% or more and 99% or more ("very pure" compounds), as listed in the text description. Such "very pure" compounds of the invention are also included herein as part of the invention.
All configurational isomers of the compounds of the present invention are within the scope of coverage, whether in mixtures, pure or very pure form. The definition of compounds in the present invention includes both the cis (Z) and the trans (E) olefin isomers, as well as the cis and trans isomers of carbocycles and heterocycles.
Throughout the specification, groups and substituents may be selected to provide stable fragments and compounds.
Specific functional groups and chemical term definitions are described in detail below. For the purposes of the present invention, chemical elements are described in conjunction with Periodic Table of the Elements, CAS version, handbook of Chemistry and Physics,75 th Ed.. The definition of specific functional groups is also described herein. Furthermore, the basic principles of organic chemistry and specific functional groups and reactivities are described in "Organic Chemistry", thomas Sorrell, university Science Books, sausalato 1999, which is incorporated by reference in its entirety.
Certain compounds of the invention may exist in specific geometric or stereoisomeric forms. The present invention encompasses all compounds, including cis and trans isomers, R and S enantiomers, diastereomers, (D) isomers, (L) isomers, racemic mixtures, and other mixtures thereof. In addition, an asymmetric carbon atom may represent a substituent such as an alkyl group. All isomers and mixtures thereof are encompassed by the present invention.
According to the invention, the mixture of isomers may contain various isomer ratios. For example, in a mixture of only two isomers, there may be a combination of: all ratios of 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0 isomers are within the scope of the invention. Similar ratios, as well as ratios for more complex mixtures of isomers, are within the scope of the present invention, as would be readily understood by one of ordinary skill in the art.
The present invention also includes isotopically-labeled compounds, equivalent to those disclosed herein as original compounds. In practice it will often occur that one or more atoms are replaced by an atom of a different atomic weight or mass number than it is. Examples of isotopes that can be listed as compounds of the invention include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine isotopes, respectively, such as 2 H、 3 H、 13 C、 11 C、 14 C、 15 N、 18 O、 17 O、 31 P、 32 P、 35 S、 18 F and F 36 Cl. The compounds of the present invention, or enantiomers, diastereomers, isomers, or pharmaceutically acceptable salts or solvates thereof, wherein isotopes or other isotopic atoms containing such compounds are within the scope of the present invention. Certain isotopically-labeled compounds of the present invention, e.g 3 H and 14 radioisotopes of C are also useful in, among other things, tissue distribution experiments of drugs and substrates. Tritium, i.e. tritium 3 H and carbon-14, i.e 14 C, their preparation and detection are relatively easy. Is the first choice in isotopes. Furthermore, heavier paritySubstitution of elements, e.g. deuterium, i.e 2 H may be preferred in some cases because of its good metabolic stability, which may be advantageous in certain therapies, such as increasing half-life or decreasing dosage in vivo. Isotopically-labeled compounds can be prepared by conventional methods by using readily available isotopically-labeled reagents in place of non-isotopically-labeled reagents using the protocols disclosed in the examples.
If one is to design the synthesis of a particular enantiomer of a compound of the invention, it may be prepared by asymmetric synthesis or by derivatization with chiral auxiliary, separating the resulting diastereomeric mixture and removing the chiral auxiliary to give the pure enantiomer. Alternatively, if the molecule contains a basic functional group, such as an amino acid, or an acidic functional group, such as a carboxyl group, diastereomeric salts can be formed therewith using an appropriate optically active acid or base, and then the resulting mixture can be separated by conventional means such as fractional crystallization or chromatography to give the pure enantiomer.
As described herein, the compounds of the present invention may be substituted with any number of substituents or functional groups to extend their inclusion. In general, the term "substituted", whether appearing before or after the term "optional", in the formulas of the present invention includes substituents, means that the specified structural substituent is substituted for the hydrogen radical. When multiple of a particular structure are substituted at a position with multiple particular substituents, the substituents may be the same or different at each position. The term "substitution" as used herein includes all permissible organic compound substitutions. In a broad sense, permissible substituents include acyclic, cyclic, branched, unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic organic compounds. In the present invention, the heteroatom nitrogen may have a hydrogen substituent or any of the permissible organic compounds described hereinabove to supplement the valence state thereof. Furthermore, the present invention is not intended to be limited in any way to allow substitution of organic compounds. The present invention recognizes that the combination of substituents and variable groups is very good in the treatment of diseases in the form of stable compounds. The term "stable" as used herein refers to a compound that is stable for a period of time sufficient to maintain structural integrity of the compound, preferably for a period of time sufficient to be effective, as used herein for the purposes described above.
Metabolites of the compounds and pharmaceutically acceptable salts thereof of the present application, as well as prodrugs that can be converted in vivo to structures of the compounds and pharmaceutically acceptable salts thereof of the present application are also encompassed by the claims of the present application.
Process for the preparation of compounds
The following schemes and examples describe methods for preparing compounds of formula I. The starting materials and intermediates are purchased from commercial sources, prepared by known procedures, or otherwise described. In some cases, the order of the steps of the reaction scheme may be altered to promote the reaction or to avoid unwanted side reaction products.
Typically, in the preparation scheme, each reaction is carried out in an inert solvent at a temperature ranging from room temperature to reflux temperature (e.g., 0 ℃ to 150 ℃, preferably 10 ℃ to 100 ℃). The reaction time is usually 0.1 hours to 60 hours, preferably 0.5 to 48 hours.
Preferably, the compounds of the present application can be prepared as follows
In the presence of a catalyst (such as HATU, potassium carbonate, etc.) in an inert solvent (such as DCM, DMF, etc.), the compound I' is reacted to give the compound I
In the method, in the process of the application,
R 1 、R 2 、R 3 the definitions of m, n, k and l are as described above;
r is selected from the group consisting of substituted or unsubstituted: C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, 3-to 10-membered heterocycloalkyl, C3-C10 cycloalkyl, 5-to 12-membered heteroaryl, C6-C12 aryl;
B' is selected from the group consisting of: amino, hydroxy, carboxyl, sulfonic acid group,-CO-NH-R';
C' is selected from: amino, hydroxy, carboxyl, sulfonic acid group,CO-O-R'、-CO-NH-R';
Wherein R' is selected from the group consisting of substituted or unsubstituted: C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, 3-to 10-membered heterocyclyl, C3-to C10-cycloalkyl, 5-to 12-membered heteroaryl, C6-to C12-aryl;
the substitution means substitution with one or more groups selected from the group consisting of: halogen, amino, nitro, hydroxyl, mercapto, cyano, carboxyl, sulfone, sulfoxide, amide, sulfonamide, ester, formyl, carboxamide, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, 3-to 10-membered heterocycloalkyl, C3-to 10-cycloalkyl, 5-to 12-membered heteroaryl and C6-C12-aryl.
Starting materials and reagents used in the methods of synthesizing the compounds of the invention are commercially available or are synthesized by methods reported in the literature.
Pharmaceutical compositions and methods of administration
Since the compound of the present invention has excellent JAK kinase inhibitory activity, the compound of the present invention or a stereoisomer or optical isomer, pharmaceutically acceptable salt, prodrug or solvate thereof, and a pharmaceutical composition containing the compound of the present invention as a main active ingredient can be used for preventing and/or treating (stabilizing, alleviating or curing) JAK kinase-associated diseases (for example, skin diseases, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriatic arthritis, juvenile arthritis, crohn's disease, myasthenia gravis, cancers (including prostate cancer, kidney cancer, liver cancer, breast cancer, lung cancer, thyroid cancer, kaposi's sarcoma, giant lymphoproliferative diseases, pancreatic cancer, leukemia, lymphoma or multiple myeloma, etc.)).
The pharmaceutical compositions of the present invention comprise a safe and effective amount of a compound of the present invention within a pharmaceutically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical compositions contain 1-2000mg of the compound of the invention per dose, more preferably 10-200mg of the compound of the invention per dose. Preferably, the "one dose" is a capsule or tablet.
"pharmaceutically acceptable carrier" means: one or more compatible solid or liquid filler or gel materials which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. "compatible" as used herein means that the components of the composition are capable of blending with and between the compounds of the present invention without significantly reducing the efficacy of the compounds. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g. sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g. stearic acid, magnesium stearate), calcium sulphate, vegetable oils (e.g. soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g. propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (e.g. tween ) Wetting agents (such as sodium lauryl sulfate), coloring agents, flavoring agents, stabilizing agents, antioxidants, preservatives, pyrogen-free water and the like.
The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, parenteral (intravenous, intramuscular or subcutaneous).
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is admixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) Fillers or compatibilizers, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) Binders, for example, hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, e.g., glycerin; (d) Disintegrants, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) a slow solvent, such as paraffin; (f) an absorption accelerator, e.g., a quaternary amine compound; (g) Wetting agents, such as cetyl alcohol and glycerol monostearate; (h) an adsorbent, for example, kaolin; and (i) a lubricant, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Solid dosage forms such as tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be released in a delayed manner in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. The active compound may also be in the form of microcapsules with one or more of the above excipients, if desired.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, in particular, cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of these substances and the like.
In addition to these inert diluents, the compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar-agar or mixtures of these substances, and the like.
Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
The compounds of the invention may be administered alone or in combination with other pharmaceutically acceptable compounds (e.g., JAK inhibitors).
When administered in combination, the pharmaceutical compositions also include combinations with one or more (2, 3, 4, or more) other pharmaceutically acceptable compounds (e.g., JAK inhibitors). One or more (2, 3, 4, or more) of the other pharmaceutically acceptable compounds (e.g., JAK inhibitors) may be used simultaneously, separately or sequentially with the compounds of the invention for preventing and/or treating diseases associated with the activity or expression level of JAK kinase.
When a pharmaceutical composition is used, a safe and effective amount of the compound of the present invention is applied to a mammal (e.g., a human) in need of treatment, wherein the dose at the time of administration is a pharmaceutically effective dose, and the daily dose is usually 1 to 2000mg, preferably 20 to 500mg, for a human having a body weight of 60 kg. Of course, the particular dosage should also take into account factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled practitioner.
The invention has the main advantages that:
1. the compound disclosed by the invention is novel in structure and has an excellent JAK kinase inhibition effect;
2. the compounds of the present invention are useful as JAK kinase inhibitors, particularly as highly selective inhibitors of JAK 1.
3. The compound has better pharmacokinetic property and drug effect, such as better drug forming property, low toxic and side effect, good bioavailability and the like.
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental methods, in which specific conditions are not noted in the following examples, are generally conducted under conventional conditions or under conditions recommended by the manufacturer. Percentages and parts are weight percentages and parts unless otherwise indicated.
The experimental materials and reagents used in the following examples were obtained from commercial sources unless otherwise specified.
Examples
General materials and test methods:
the synthetic methods of the compounds of the present invention are shown in the schemes, methods and examples below. The starting materials are commercially available or may be prepared according to known methods described in the art or herein. The compounds of the present invention are illustrated by the specific examples shown below. However, these specific embodiments should not be construed as the only kind of the invention. These examples further illustrate the preparation of the compounds of the present invention. Those skilled in the art will readily appreciate that known variations of conditions and procedures may be used to prepare these compounds.
All temperatures are in degrees celsius unless otherwise indicated.
The percentages for the yields are mass percentages.
All parts are parts by volume and all percentages are percentages by volume unless otherwise indicated.
Thin Layer Chromatography (PTLC) was performed on a 20X 20cm plate (500 μm thick silica gel). Silica gel chromatography was performed using a Biotage flash chromatography system.
1 H NMR was performed with a Bruker AscendTM400 spectrometer, 400mhz,298k, and the chemical shift (ppm) of residual protons in deuterated reagent gave a reference:
CDCl 3 δ=7.26ppm,CD 3 ODδ=3.30ppm,DMSO-d 6 δ=2.50ppm
LCMS chromatography uses agilent technology 1260 linked 6100 quadrupole spectrometer. For LC mobile phase 0.1% formic acid-water (a) and 0.1% formic acid-acetonitrile (B), eluent gradient: 0-5.5 min 0-95% B,5.5-6 min 95% B,6-8 min 0% B with SB-Aq capillary column of 50 mm. Times.2.1 mm. Times.3.5. Mu.m.
Mass Spectrometry (MS) was determined by electrospray ion mass spectrometry (ESI).
HPLC mass spectrometry conditions:
LC1:
column: SB-Aq50 mm. Times.2.1 mm. Times.3.5. Mu.m;
temperature: 40 ℃;
eluent: 100:0 to 5:95 v/v 0.1% formic acid-water/0.1% formic acid-acetonitrile for 8 minutes;
flow rate: 1.0mL/min, 5. Mu.L;
and (3) detection: VWD,210nm &254nm;
MS: the mass range is 100-100amu; positive ion electrospray ionization.
Abbreviation table:
AcOH = acetic acid
Alk is an alkyl group
AR is aryl
Boc=t-butoxycarbonyl group
bs=broad peak
CH 2 Cl 2 =dichloromethane
d=bimodal
dd = double doublet
Dbu=1, 8-diazabicyclo [5.4.0] undec-7-ene
Dcm=dichloromethane
Dmf=n, N-dimethylformamide
DMSO = dimethyl sulfoxide
Ea=ethyl acetate
ESI = electrospray ionization
Et=ethyl group
EtOAc = ethyl acetate
Etoh=ethanol
h=h
Hoac=acetic acid
Lioh=lithium hydroxide
m = multiple
Me=methyl group
Mecn=acetonitrile
Meoh=methanol
MgSO 4 =magnesium sulfate
min = min
Ms=mass spectrum
Nacl=sodium chloride
NaOH = sodium hydroxide
Na 2 SO 4 Sodium sulfate =
Nmr=nuclear magnetic resonance spectroscopy
Pe=petroleum ether
PG = protecting group
Ph=phenyl
rt=room temperature
s = single peak
t=triplet
TFA = trifluoroacetic acid
THF = tetrahydrofuran
Synthesis of example 1 A1:
the first step: 2- (1, 4-dioxaspiro [4.5] dec-8-ylidene) acetic acid ethyl ester (A1-2)
1, 4-cyclohexanedione monoethyl glycol ketal (A1-1, 10.0g,64.0 mmol) was added to anhydrous THF (100 ml) under nitrogen protection, stirred in an ice bath for 5min, sodium hydrogen (3.07g,76.8mmol,60%dispersion in mineral oil) was added in portions, stirring in an ice bath was continued for 0.5h, then a solution of triethyl phosphonoacetate (14.78 g,65.9 mmol) in THF (50 ml) was slowly added, and after dropping naturally warmed to room temperature and stirring continued for 2h. After TLC confirmed the completion of the reaction, water quenching, concentrating THF, extracting with EA, collecting the organic layer, drying over anhydrous sodium sulfate, concentrating EA to give 2- (1, 4-dioxaspiro [4.5] as a yellow liquid]Decyl-8-subunit) ethyl acetate (A1-2, 14.38g, trude) was used directly in the next step without purification. 1 H NMR(400MHz,CDCl 3 )δ5.69(s,1H),4.17(q,J=8.0Hz,2H),4.00(s,4H),3.04-3.01(m,2H),2.42-2.39(m,2H),1.82-1.77(m,4H),1.30(t,J=8.0Hz,3H)。
And a second step of: 2- (8-Nitromethyl-1, 4-dioxaspiro [4.5] dec-8-yl) acetic acid ethyl ester (A1-3)
2- (1, 4-dioxaspiro [4.5] ]Ethyl dec-8-ylidene acetate (A1-2, 14.38g,63.6 mmol) was added to THF (100 ml), followed by tetrabutylammonium fluoride (18.29g,70mmol,70mL,1M in THF) and nitromethane (5.82 g,95.40 mmol) in this order, and the temperature was raised to 80℃and the reaction was stirred for 16h. After TLC confirmed the completion of the reaction, THF was concentrated, EA and deionized water were added, the separated solution was extracted, and the organic layer was dried over anhydrous sodium sulfate, and EA was concentrated to give 2- (8- (nitromethyl) -1, 4-dioxaspiro [4.5 ] as a yellow liquid]Decyl-8-yl) ethyl acetate (A1-3, 16.68g, crude) was used directly in the next step without purification. 1 H NMR(400MHz,CDCl 3 )δ4.75(s,2H),4.21-4.15(q,J=8.0Hz,2H),3.97(s,4H),2.58(s,2H),1.74-1.72(m,8H),1.31-1.25(m,3H)。
And a third step of: 1, 4-dioxa-10-azadispiro [4.2.4 8 .2 5 ]Tetradecan-11-one (A1-4)
2- (8-Nitromethyl-1, 4-dioxaspiro [4.5 ]]Decyl-8-yl) ethyl acetate (A1-3, 16.68 g) was added to methanol (150 ml), then Raney nickel was added and reacted at 45℃for 48h with hydrogen. After completion of the LCMS monitoring reaction, the reaction mixture was filtered and the methanol was concentrated to give 1, 4-dioxa-10-azadispiro [4.2.4 ] 8 .2 5 ]Tetradecan-11-one (A1-4, 11.98g, crop) was used directly in the next step without purification. 1 H NMR(400MHz,CDCl 3 )δ5.65(s,1H),3.97(s,4H),3.22(s,2H),2.26(s,2H),1.77-1.74(m,4H),1.69-1.66(m,4H)。
Fourth step: 1, 4-dioxa-10-azaspiro [4.2.4 8 .2 5 ]Tetradecane (A1-5)
Nitrogen protection, 1, 4-dioxa-10-azadispiro [4.2.4 8 .2 5 ]Tetradecan-11-one (A1-4, 2g,9.47 mmol) was added to dry THF (30 ml) and stirred for 5min, borane THF solution (47.4 ml,47.4mmol, 1M) was slowly added, warmed to 70℃and stirred for 16h. After completion of the reaction by LCMS, the reaction mixture was cooled to room temperature, quenched by slow addition of methanol, and the solvent was concentrated to give 1, 4-dioxa-10-azaspiro [4.2.4 ] as an oil 8 .2 5 ]Tetradecane (A1-5, 1.8g, crude) was used directly without purificationNext, the process is performed.
Fifth step: 10- (7H-pyrrolo [2, 3-d)]Pyrimidin-4-yl) -1, 4-dioxa-10-azaspiro [4.2.4 8 .2 5 ]Tetradecane (A1-6)
1, 4-dioxa-10-azaspiro [4.2.4 8 .2 5 ]Tetradecane (A1-5, 1.8g,9.13 mmol) and 4-chloro-7H-pyrrolo [2, 3-d)]Pyrimidine (1.4 g,9.13 mmol) was added to DMF (30 ml), followed by N, N-diisopropylethylamine (2.36 g,18.3 mmol), warmed to 100℃and stirred for 16h. After completion of the reaction, LCMS was confirmed, cooled to room temperature, suction filtered, the cake was collected, and suction dried under reduced pressure to give 10- (7H-pyrrolo [2, 3-d) as an off-white solid]Pyrimidin-4-yl) -1, 4-dioxa-10-azaspiro [4.2.4 8 .2 5 ]Tetradecane (A1-6, 2.26g, crude) was used directly in the next step without purification. 1 H NMR(400MHz,CDCl 3 )δ10.16(br,1H),8.33(s,1H),7.05(d,J=3.48Hz,1H),6.59(d,J=3.52Hz,1H),3.99–3.96(m,6H),3.73(s,2H),2.00–1.92(m,2H),1.78–1.71(m,8H)。
Sixth step: 2- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -2-aza-spiro [4.5] decan-8-one (A1-7)
10- (7H-pyrrolo [2, 3-d)]Pyrimidin-4-yl) -1, 4-dioxa-10-azaspiro [4.2.4 8 .2 5 ]Tetradecane (A1-6, 2.26g,7.20 mmol) was added to THF (30 ml), concentrated hydrochloric acid (10 ml) was added dropwise thereto, and the mixture was stirred at room temperature for 16h. After the completion of the reaction, 6mol/L NaOH solution is added dropwise to adjust the pH value to be 7-8, the filtration is carried out, a filter cake is collected, and the filtration is carried out under reduced pressure and dried to obtain an off-white solid 2- (7H-pyrrolo [2, 3-d) ]Pyrimidin-4-yl) -2-aza-spiro [4.5]Decan-8-one (A1-7, 1.89g, crop) was used directly in the next step without purification. 1 H NMR(400MHz,CDCl 3 )δ10.63(br,1H),8.35(s,1H),7.09(d,J=4Hz,1H),6.61(d,J=4.0Hz,1H),4.05(s,2H),3.89(s,2H),2.48(t,J=8.0Hz,4H),2.12(t,J=8.0Hz,2H),2.07–1.96(m,4H)。
Seventh step: 2- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -2-azaspiro [4.5] decan-8-amine (A1)
2- (7H-pyrrolo [2, 3-d)]Pyrimidin-4-yl) -2-azaspiro [4.5]Decan-8-one (A1-7, 1g,3.70 mmol) was added to absolute ethanol (30 ml), followed by 7mol/L NH 3 (MeOH) (29.6 ml,0.21 mol) and isopropyl titanate (2.1 g,7.40 mmol), stirred at room temperature for 6h, then sodium borohydride (210 mg,5.56 mmol) was added in portions and stirring was continued for 16h. After LCMS confirmed the completion of the reaction, the reaction was quenched by addition of aqueous ammonia (17 ml), stirred at room temperature for 15min, suction filtered, the filtrate collected, concentrated, added with EA, stirred for 10min, suction filtered, the filter cake collected, and dried in vacuo to give an off-white solid A1 (900 mg). MS (ESI) M/z calcd 272.19 (M+H), found 272.10; 1 H NMR(400MHz,DMSO- d6 )δ11.55(br,1H),8.06(s,1H),7.09(d,J=3.32Hz,1H),6.57(s,1H),3.79(s,2H),3.49(s,2H),2.71-2.68(m,1H),1.87(s,2H),1.72-1.69(m,2H),1.64-1.61(m,2H),1.43(s,2H),1.33-1.27(m,2H)。
example 2 synthesis of N- (2- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -2-azaspiro [4.5] dec-8-yl) acetamide (A2):
nitrogen protection, 2- (7H-pyrrolo [2, 3-d)]Pyrimidin-4-yl) -2-azaspiro [4.5]Decan-8-amine (A1, 4mg, 14.8. Mu. Mol) was added to MeCN (1 ml), sodium bicarbonate (2 mg, 23.8. Mu. Mol) was added, and the mixture was cooled to 0℃and stirred for 5min, and then a MeCN solution of acetyl chloride (1.1 mg, 14.8. Mu. Mmol) was added dropwise thereto, and ice-bath stirring was continued for 1h. After LCMS confirmed the reaction was complete, meCN was concentrated and the residue was purified by prep. to give A2 as a white solid (3 mg, 64.9% yield). MS (ESI) M/z calcd314.20 (M+H), found 314.00; 1 H NMR(400MHz,MeOH- d4 )δ8.08(s,1H),7.10(d,J=3.56Hz,1H),6.71(d,J=3.56Hz,1H),3.91(br,2H),3.73-3.63(m,3H),2.06-2.04(m,2H),1.95(s,3H),1.88-1.85(m,2H),1.79-1.75(m,2H),1.65-1.59(m,2H),1.53-1.45(m,2H)。
Example 3 synthesis of N- (2- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -2-azaspiro [4.5] dec-8-yl) benzenesulfonamide (A3:
nitrogen protection, 2- (7H-pyrrolo [2, 3-d)]Pyrimidin-4-yl) -2-azaspiro [4.5]Decan-8-amine (A1, 10mg, 36.9. Mu. Mol) was added to DMF (2 ml), dissolved by stirring, potassium carbonate (6.1 mg, 44.2. Mu. Mol) was added, followed by dropwise addition of a solution of benzenesulfonyl chloride (7.8 mg, 44.2. Mu. Mol) in DMF (0.5 ml) and stirring at room temperature for 1h. After LCMS confirmed completion of the reaction, EA and deionized water were added for extraction, the organic phase was collected, EA was concentrated, and the residue was purified by reverse phase column to give A3 as a white solid (5 mg, yield 33.1%). MS (ESI) M/z calcd 412.18 (M+H), found 412.20; 1 H NMR(400MHz,DMSO- d6 )δ12.65(br,1H),8.27(d,J=8.0Hz,1H),7.84(d,J=8.0Hz,2H),7.71(d,J=8.0Hz,1H),7.66-7.58(m,3H),7.43(br,1H),6.88(br,1H),3.99(br,1H),3.63(br,3H),3.02(br,1H),1.92-1.85(m,2H),1.61-1.59(m,4H),1.39-1.32(m,4H)。
example 4 synthesis of N-2- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -2-azaspiro [4.5] dec-8-yl) -3-bromo-5-nitrobenzamide (A4):
nitrogen protection, 2- (7H-pyrrolo [2, 3-d)]Pyrimidin-4-yl) -2-azaspiro [4.5]Decan-8-amine (A1, 15mg, 55.3. Mu. Mol) and 3-bromo-5-nitrobenzoic acid (13.5 mg, 55.3. Mu. Mol) were added to a mixture of DCM (2 ml) and DMF (0.5 ml), HATU (21 mg, 55.3. Mu. Mol) was added and stirred in an ice bath for 5min, then a solution of N, N-diisopropylethylamine (7.1 mg, 55.3. Mu. Mol) in DCM (1 ml) was added dropwise and stirred in an ice bath for 0.5h. After LCMS confirmed the reaction was complete, dichloromethane and deionized water were added and the organic layer was collected, anhydrous Na 2 SO 4 Dried, concentrated DCM and the residue purified by reverse phase column to give a white solid A4 (11 mg, 40.0% yield). MS (ESI) M/z calcd 499.11, 501.11 (M+H), found 499.21, 501.22; 1 H NMR(400MHz,DMSO- d6 )δ12.66(br,1H),8.74(d,J=8.0Hz,1H),8.66-8.65(m,1H),8.56(d,J=1.48Hz,1H),8.49-8.48(m,1H),8.30(d,J=4.0Hz,1H),7.45(s,1H),6.94(s,1H),4.04-3.87(m,5H),2.05-1.75(m,6H),1.59-1.52(m,4H)。
prepared with reference to the experimental procedure of examples 2-4, with different acylating reagents, gave examples 5-75, as shown in table 1 below.
TABLE 1
EXAMPLE 76 Synthesis of N- (2- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -2-azaspiro [3.3] hept-6-yl) -2-chloro-4-nitrobenzamide (76)
The first step: 6-oxo-2-azaspiro [3.3] heptane (A76-01)
2-Boc-6-oxo-2-azaspiro [3.3] heptane (200 mg,0.95 mmol) was added to DCM (2 mL), trifluoroacetic acid (2 mL) was added under nitrogen and stirred at room temperature for 3.0h. After LCMS confirmed the reaction was complete, the reaction mixture was directly dried by spin to give 6-oxo-2-azaspiro [3.3] heptane trifluoroacetate (a 76-01, 215mg, crude) as a yellow oil, which was used directly in the next step without purification. MS (ESI) M/z calcd 112.07 (M+H), found 112.14.
And a second step of: 6-oxo-2- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -2-azaspiro [3.3] heptane (A76-02)
6-oxo-2-azaspiro [3.3] heptane trifluoroacetate (A76-01, 215mg,0.95 mmol) and 4-chloro-7H-pyrrolo [2,3-d ] pyrimidine (148 mg,0.96 mmol) were added to N-methylpyrrolidone (4 ml), followed by potassium carbonate (900 mg,6.5 mmol), and the mixture was stirred for 14H at 80 ℃. After LCMS confirmed completion of the reaction, cooled to room temperature, suction filtered, the filter cake was collected, and suction dried under reduced pressure to give 6-oxo-2- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -2-azaspiro [3.3] heptane (a 76-02, 40mg, crude) as an off-white solid, which was used directly in the next step without purification.
And a third step of: 2- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -2-azaspiro [3.3] hept-6-amine (A76-03)
6-oxo-2- (7H-pyrrolo [2, 3-d)]Pyrimidin-4-yl) -2-azaspiro [3.3]Heptane (A76-02, 40mg,0.18 mmol) was added to absolute ethanol (2 ml), followed by 7mol/L NH 3 Is stirred at room temperature for 6h with isopropyl titanate (105 mg,0.37 mmol) and MeOH (2 ml,14 mmol) and sodium borohydride (67 mg,1.8 mmol) is added and stirring is continued for 16h. After completion of the reaction by LCMS, the reaction was quenched by adding ammonia (2 mL), stirring at room temperature for 15min, suction filtration, collecting the filtrate, concentrating, adding EA for dissolution, suction filtration, collecting the filtrate, and spin-drying under reduced pressure to give 2- (7H-pyrrolo [2, 3-d) as a pale yellow oil]Pyrimidin-4-yl) -2-azaspiro [3.3]Hept-6-amine (A76-03, 35mg, trude) was used directly in the next step without further treatment. MS (ESI) M/z calcd 229.13 (M+H), found 229.10.
Fourth step: n- (2- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -2-azaspiro [3.3] hept-6-yl) -4-chloro-2-nitrobenzamide (A76)
2- (7H-pyrrolo [2, 3-d)]Pyrimidin-4-yl) -2-azaspiro [3.3]Hept-6-amine (A76-03, 35mg,0.15 mmol) and 4-chloro-2-nitrobenzoic acid (30 mg,0.15 mmol) were added to DMF (1 ml), HATU (57 mg,0.15 mmol) was added thereto, stirred in an ice bath for 5min, and then N, N-diisopropylethylamine (19.35 mg, A solution of 0.15mmol of DMF (0.5 mL) was stirred in an ice bath for 1h. After LCMS confirmed the reaction was complete, the reaction was directly purified by reverse phase column to give a76 as a white solid (20 mg, yield 32.3%). MS (ESI) M/z calcd 413.11 (M+H), found 413.10; 1 H NMR(400MHz,DMSO- d6 )δ12.64(s,1H),8.97(d,J=6.9Hz,1H),8.30(s,1H),8.19(s,1H),7.91(d,J=8.2Hz,1H),7.67(d,J=8.2Hz,1H),7.45(s,1H),6.70(s,1H),4.53(m,4H),4.26-4.22(m,1H),2.78–2.64(m,2H),2.35-2.30(m,2H)。
effect example 1: biological testing method
The method for measuring and activating JAK kinase uses homogeneous time-resolved fluorescence technology. The reaction of this method was carried out in 384 shallow well plates in a total reaction volume of 10. Mu.L. A mixture of kinase protein, compound, ATP and substrate was incubated at 50mM Hepes (pH 7.0), naN 3 0.02%, BSA 0.01%, 0.1mM orthovanadate (orthovanadate), 5mM MgCl 2 1mM DTT in reaction buffer, after 1 hour of reaction, an antibody recognizing substrate phosphorylation and dye XL-615 and EDTA-containing detection buffer (Cisbio) were added to the system. The reaction signal of the kinase was detected by a multi-well plate detector from PE company. The parameter settings are excitation light 320nm, emission light 615nm and 665nm. JAK viability is indirectly reflected by the ratio of 665nm to 615nm signals. The reaction was set with background wells without enzyme and wells with total enzyme activity without compound.
Compound arrestin IC 50 The value of (2) is calculated by the formula: y=100/(1+10 ((log ic 50-X)) HillSlope).
In the JAK1 reaction system, the ATP concentration was 2. Mu.M, and the JAK1 protein concentration was 0.2 ng/. Mu.L.
In the JAK2 reaction system, the ATP concentration was 2. Mu.M, and the JAK1 protein concentration was 0.01 ng/. Mu.L.
In the JAK3 reaction system, the ATP concentration was 2. Mu.M, and the JAK1 protein concentration was 0.04 ng/. Mu.L.
In the TYK2 reaction system, the ATP concentration was 2. Mu.M, and the JAK1 protein concentration was 0.2 ng/. Mu.L.
The test data are divided into the following: a: IC 50 <10nM;B:IC 50 11-100nM;C:IC 50 101-1000nM;D:IC 50 1001-10000nM;E:IC 50 >10000nM。
The test results are shown in Table 2.
TABLE 2
The experimental results suggest that:
(1) The compounds of formula I of the present application exhibit very excellent JAK inhibiting activity, in particular JAK1 activity. The compounds of the application may have IC50 values as low as 10nM or less, so that daily doses of typically 10mg to 30mg are extremely effective in inhibiting JAK, particularly JAK1, in subjects (such as patients, particularly rheumatoid arthritis or psoriasis patients) weighing about 70 kg.
(2) The compounds of formula I of the present application exhibit very excellent JAK selectivity, i.e., a ratio of IC50 of JAK3/JAK1, a ratio of IC50 of JAK2/JAK1, a ratio of IC50 of TYK2/JAK1 is increased by about 10-fold (mostly about 20-100-fold), which is far superior to drugs currently on the market.
All documents mentioned in this disclosure are incorporated by reference in this disclosure as if each were individually incorporated by reference. Further, it will be appreciated that various changes and modifications may be made by those skilled in the art after reading the above teachings, and such equivalents are intended to fall within the scope of the application as defined in the appended claims.
Claims (10)
- A compound of formula I or a stereoisomer or optical isomer, pharmaceutically acceptable salt, prodrug or solvate thereof,in the method, in the process of the invention,R 1 、R 2 and R is 3 Each independently selected from the group consisting of substituted or unsubstituted: H. d, halogen, amino, nitro, hydroxy, cyano, carboxyl, sulfone, sulfoxide, amide, sulfonamide, ester, formyl, carboxamide, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, 3-C10 membered heterocycloalkyl, C3-C10 cycloalkyl, 5-12 membered heteroaryl, C6-C12 aryl; wherein said substitution means by one or more R a Substitution;or R is 1 And R is 2 Together with the atoms to which they are attached, constitute a substituted or unsubstituted group of radicals: 5-6 membered aryl or heteroaryl, 3-10 membered heterocyclyl, C3-C10 cycloalkyl; wherein said substitution means by one or more R a Substitution;b is independently selected from the group consisting of: bond, - (CH) 2 ) r -、C(=O)、N-R b 、C(=O)O-、 -(CH 2 ) p -R c 、O、S、SO、SO 2 ;R c Selected from: c (=O) O-, C (=O) O-Wherein R is b Independently selected from the group consisting of: H. C1-C6 alkyl;wherein- (CH) 2 ) r -and- (CH) 2 ) p The H atom in-can optionally be replaced by one or more R a Substitution;c is selected from the group consisting of substituted or unsubstituted: H. C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, 3-to 10-membered heterocycloalkyl, C3-C10 cycloalkyl, 5-to 12-membered heteroaryl, C6-C12 aryl; wherein said substitution means by one or more R a Substitution;r and p are each independently 1, 2, 3, 4;m, n, k and l are each independently 0, 1, 2, 3, and m+n is not less than 1, k+l is not less than 1;h in the moiety may optionally be substituted with one or more R a Substitution;wherein each R a Independently selected from the group consisting of substituted or unsubstituted: halogen, amino, nitro, hydroxyl, mercapto, cyano, carboxyl, sulfone, sulfoxide, amide, sulfonamide, ester, formyl, carboxamide, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, 3-C10 membered heterocycloalkyl, C3-C10 cycloalkyl, 5-12 membered heteroaryl and C6-C12 aryl; wherein R is a By substitution is meant substitution with one or more groups selected from the group consisting of: halogen, amino, nitro, hydroxyl, mercapto, cyano, carboxyl, sulfone, sulfoxide, amide, sulfonamide, ester, formyl, carboxamide, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, 3-to 10-membered heterocycloalkyl, C3-to 10-cycloalkyl, 5-to 12-membered heteroaryl and C6-C12-aryl.
- A compound of claim 1, or a stereoisomer or optical isomer, pharmaceutically acceptable salt, prodrug or solvate thereof, The moiety is selected from:wherein q is 0, 1, 2, 3, 4 or 5;R a is defined as in claim 1.
- A compound according to claim 1, or a stereoisomer or optical isomer, pharmaceutically acceptable salt, prodrug or solvate thereof, having the structure of formula II:wherein q is 0, 1, 2, 3, 4 or 5;R 1 、R 2 、R 3 、R a the definitions of B and C are as defined in claim 1.
- A compound according to claim 1, or a stereoisomer or optical isomer, pharmaceutically acceptable salt, prodrug or solvate thereof, wherein B is selected from the group consisting of: c (=O) O-, C (=O) O-Wherein R is b Is defined as in claim 1.
- The compound of claim 1 or a stereoisomer thereofOr an optical isomer, a pharmaceutically acceptable salt, prodrug or solvate, characterized in that C is selected from the group consisting of substituted or unsubstituted: 3-8 membered heterocycloalkyl, C3-C8 cycloalkyl, 5-10 membered heteroaryl, C6-C10 aryl; wherein said substitution means by one or more R a Substitution;R a is defined as in claim 1.
- The compound of claim 1, or a stereoisomer, or optical isomer, pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein the compound satisfies one or more of the following conditions,(1) Selected from:wherein q is 0, 1, 2, 3, 4 or 5; r is R a Is as defined in claim 1;(2) B is selected from: -NH-,-NH-C (=o) -; optionally, each hydrogen in the above groups is substituted with a C1-C6 alkyl group;(3) C is selected from: H. methoxy, phenyl, methyl, ethyl, thiazolyl, pyridyl, cyclopropyl, pyrazinyl, cyclohexyl, benzothienyl, benzofuranyl, pyrimidinyl, naphthyl, cyclobutyl, cyclopentyl, cycloheptyl; wherein, optionally, C is substituted with a substituent selected from the group consisting of: fluorine, chlorine, bromine, nitro, cyano, hydroxy, ethynyl, methyl, methoxy, methyl formate, trifluoromethyl, phenyl, sulfonamide;preferably, C is selected from: H. methoxy, phenyl, methyl,Cyclopropyl group,Cyclohexyl group,Naphthyl, cyclobutyl, cyclopentyl, cycloheptyl; wherein, optionally, C is substituted with a substituent selected from the group consisting of: fluorine, chlorine, bromine, nitro, cyano, hydroxy, ethynyl, methyl, methoxy, methyl formate, trifluoromethyl, phenyl, sulfonamide;more preferably, C is selected from: H. methyl, methoxy, Phenyl group,(4)R 1 Is hydrogen;(5)R 2 is hydrogen;(6)R 3 is hydrogen;in particular the number of the elements to be processed,selected from the group consisting of
- The compound of any one of claim 1 to 5, or a stereoisomer, or an optical isomer, a pharmaceutically acceptable salt, a prodrug, or a solvate thereof, wherein each substituent satisfies one or more of the following conditions,Each C1-C6 alkyl is independently selected from: methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl;each C1-C6 alkoxy is independently selected from: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy;each C2-C6 alkenyl is independently selected from: ethenyl, propenyl, allyl;each C2-C6 alkynyl is independently selected from: ethynyl, propynyl;each 3-10 membered heterocycloalkyl is independently selected from: tetrahydrofuranyl, tetrahydropyrrolyl, tetrahydrothiophene, tetrahydropyranyl, piperazinyl, piperidinyl, morpholinyl;each C3-C10 cycloalkyl is independently selected from: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl;each 5-12 membered heteroaryl is independently selected from: pyrrolyl, furanyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, thiazolyl, indolyl, benzothienyl, benzofuranyl;each C6-C12 aryl is independently selected from: phenyl and naphthyl.
- The compound of claim 1, or a stereoisomer or optical isomer, pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein the compound is selected from the group consisting of:
- A pharmaceutical composition comprising a compound according to any one of claims 1 to 8, or a stereoisomer or optical isomer, a pharmaceutically acceptable salt, prodrug or solvate thereof; and a pharmaceutically acceptable carrier;in particular, the pharmaceutical composition is useful for treating or preventing diseases associated with the activity or expression of JAK kinase;more particularly, the pharmaceutical composition is useful as a JAK kinase inhibitor, preferably as a JAK1 kinase inhibitor.
- The use of a compound according to any one of claim 1 to 8, or a stereoisomer or an optical isomer, a pharmaceutically acceptable salt, a prodrug or a solvate thereof,it is used for preparing a medicament or a pharmaceutical composition for treating or preventing diseases related to the activity or expression amount of JAK kinase; alternatively, it is used for the preparation of a medicament or pharmaceutical composition for inhibiting JAK kinase activity, preferably JAK1 kinase;in particular, the disease is selected from the group consisting of: cancer, myeloproliferative diseases, inflammation, immune diseases, organ transplantation, viral diseases, cardiovascular diseases or metabolic diseases, autoimmune diseases of humans or animals, rheumatoid arthritis, skin disorders, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, myasthenia gravis, psoriasis; wherein the cancer is preferably selected from the group consisting of: prostate cancer, kidney cancer, liver cancer, breast cancer, lung cancer, thyroid cancer, kaposi's sarcoma, giant lymphoproliferative disorders, pancreatic cancer, leukemia, lymphoma, multiple myeloma;In particular, the disease associated with the activity or expression level of JAK kinase is a JAK 1-related disorder; wherein the JAK 1-associated disorder is preferably selected from the group consisting of: type I diabetes, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, crohn's disease and alopecia areata.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011399496 | 2020-12-02 | ||
CN2020113994966 | 2020-12-02 | ||
PCT/CN2021/134880 WO2022117012A1 (en) | 2020-12-02 | 2021-12-01 | Spirocyclic jak inhibitor, pharmaceutical composition containing same, and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116783198A true CN116783198A (en) | 2023-09-19 |
Family
ID=81852954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180080571.9A Pending CN116783198A (en) | 2020-12-02 | 2021-12-01 | Spirocyclic JAK inhibitor, pharmaceutical composition containing same and application of spiro JAK inhibitor |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116783198A (en) |
WO (1) | WO2022117012A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105732636B (en) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | Heteroaromatic compounds and their use in medicine |
US10799507B2 (en) * | 2017-02-03 | 2020-10-13 | Leo Pharma A/S | 5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2.5]octane-8-carboxylic acid derivatives as novel JAK kinase inhibitors |
-
2021
- 2021-12-01 CN CN202180080571.9A patent/CN116783198A/en active Pending
- 2021-12-01 WO PCT/CN2021/134880 patent/WO2022117012A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2022117012A1 (en) | 2022-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2969090C (en) | Triazolopyrimidine compounds and uses thereof | |
US20230118795A1 (en) | Aryl or heteroaryl pyridone or pyrimidine derivative, preparation method and use thereof | |
WO2021228161A1 (en) | Alkoxlyalkyl-substituted heterocyclic inhibitor, preparation method therefor, and use thereof | |
CN115335379A (en) | Spiro-containing quinazoline compounds | |
RU2633694C2 (en) | Dyetherned phenylaminopyrimidine and pharmaceutical composition containing such connection | |
WO2022199586A1 (en) | Pyrimidopyridine inhibitor, preparation method therefor, and use thereof | |
WO2021238817A1 (en) | Macrocyclic jak inhibitor and use thereof | |
WO2021249563A1 (en) | Aryl or heteroaryl pyridone or pyrimidone derivative, preparation method therefor and application thereof | |
CA2658404A1 (en) | Selective antagonists of a2a adenosine receptors | |
CA3150284A1 (en) | Aza-quinoline compounds and uses thereof | |
WO2022095909A1 (en) | Compound used as ntrk inhibitor and application thereof | |
CN111718332B (en) | 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof | |
AU2019339994B2 (en) | Furo[3,4-b]pyrrole-containing BTK inhibitor | |
EP3854793A1 (en) | Aromatic heterocyclic compound with kinase inhibitory activity | |
CN109476643B (en) | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | |
CN110938070A (en) | Heteroaromatic compound with kinase inhibition activity | |
CN117916234A (en) | Compounds as TYK2/JAK1 pseudo-kinase domain inhibitors and methods of synthesis and use | |
CN116783198A (en) | Spirocyclic JAK inhibitor, pharmaceutical composition containing same and application of spiro JAK inhibitor | |
CN115215869A (en) | Substituted tricyclic inhibitor and preparation method and application thereof | |
CN115215844A (en) | Substituted pyrimido-ring inhibitor and preparation method and application thereof | |
CN113583020B (en) | JAK2 inhibitor and application | |
EP4159738A1 (en) | Macrocyclic jak inhibitor and uses thereof | |
CN117820305A (en) | Heterocyclic substituted quinazoline and preparation method and application thereof | |
EP4310081A1 (en) | Ctla-4 small molecule degradation agent and application thereof | |
CN116813646A (en) | Substituted bridged ring inhibitors and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |